(ELTX) Elicio Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
ELTX: Cancer, Vaccines, Immunotherapies, Peptides
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, specializes in developing innovative immunotherapies for cancer treatment. The companys lead product candidate, ELI-002, is a multivalent lymph node-targeted AMP peptide vaccine currently in Phase II clinical trials. ELI-002 specifically targets seven Kirsten rat sarcoma viral oncogene homolog (KRAS) driver mutations, which are commonly found in solid tumors such as colorectal, lung, and pancreatic cancers. Additionally, Elicio is advancing ELI-007, another multivalent lymph node-targeted AMP peptide vaccine, designed to target mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene mutations, frequently observed in melanoma and colorectal cancer. The company is also developing ELI-008, which focuses on p53 hotspot mutations, a prevalent genetic alteration across various cancers. Elicios approach leverages the lymph nodes role as a hub for immune response, aiming to enhance the bodys ability to recognize and attack cancer cells. Headquartered in Boston, Massachusetts, the company is committed to addressing significant unmet medical needs in oncology.
Based on the provided data, the 3-month forecast for Elicio Therapeutics (NASDAQ:ELTX) suggests a neutral outlook with potential for slight upward movement. Technically, the stock is trading above its 200-day simple moving average (SMA) of 5.80, indicating longer-term bullish momentum. However, the 20-day SMA of 8.33 is slightly above the current price of 8.18, suggesting short-term resistance. The average true range (ATR) of 0.64 indicates moderate volatility. From a fundamental perspective, the companys market capitalization of $102.93 million reflects its small-cap status, and the price-to-book (P/B) ratio of 10.11 highlights a premium valuation relative to book value. The return on equity (RoE) of 246.72 suggests strong profitability, though this metric must be interpreted cautiously in the context of clinical-stage biotechnology companies, where profitability often reflects R&D investments rather than operational income. Overall, while the technical indicators point to potential stability, the high P/B ratio and the speculative nature of the biotech sector warrant caution.
Additional Sources for ELTX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ELTX Stock Overview
Market Cap in USD | 125m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2021-02-05 |
ELTX Stock Ratings
Growth 5y | -70.8% |
Fundamental | -2.26% |
Dividend | 0.0% |
Rel. Strength Industry | 46.6 |
Analysts | 4/5 |
Fair Price Momentum | 5.66 USD |
Fair Price DCF | - |
ELTX Dividends
No Dividends PaidELTX Growth Ratios
Growth Correlation 3m | 72.9% |
Growth Correlation 12m | -10.6% |
Growth Correlation 5y | -88% |
CAGR 5y | -52.86% |
CAGR/Max DD 5y | -0.54 |
Sharpe Ratio 12m | 0.23 |
Alpha | 38.62 |
Beta | 0.78 |
Volatility | 88.14% |
Current Volume | 40.8k |
Average Volume 20d | 34.1k |
As of March 15, 2025, the stock is trading at USD 7.75 with a total of 40,802 shares traded.
Over the past week, the price has changed by -1.77%, over one month by -5.14%, over three months by +57.84% and over the past year by +47.90%.
Neither. Based on ValueRay Fundamental Analyses, Elicio Therapeutics is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -2.26 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ELTX as of March 2025 is 5.66. This means that ELTX is currently overvalued and has a potential downside of -26.97%.
Elicio Therapeutics has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy ELTX.
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ELTX Elicio Therapeutics will be worth about 6.2 in March 2026. The stock is currently trading at 7.75. This means that the stock has a potential downside of -20%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 12 | 54.8% |
Analysts Target Price | 9.5 | 22.6% |
ValueRay Target Price | 6.2 | -20% |